{"id":"NCT00132678","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","briefTitle":"A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes","officialTitle":"A Randomized, Double-blind, Placebo-controlled Study to Explore the Efficacy and Safety of Risperidone Long-acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar 1 Disorder, With Open-label Extension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-02","primaryCompletion":"2007-10","completion":"2007-12","firstPosted":"2005-08-22","resultsPosted":"2009-02-27","lastUpdate":"2013-07-29"},"enrollment":559,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Risperdal Consta","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"001","type":"EXPERIMENTAL"},{"label":"002","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if risperidone is effective and safe in the prevention of mood episodes in patients with bipolar 1 disorder.","primaryOutcome":{"measure":"Number of Participants Who Had a Mood Relapse.","timeFrame":"24 months","effectByArm":[{"arm":"RISPERDAL CONSTA","deltaMin":42,"sd":null},{"arm":"Placebo","deltaMin":76,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":51,"countries":["United States","Austria","India","Malaysia","Poland","Russia","Slovakia","Spain","Taiwan","Ukraine"]},"refs":{"pmids":["20227682"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=27&filename=CR002278_CSR.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":154},"commonTop":["Insomnia","Headache","Agitation","Sommolence","Anxiety"]}}